```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS  4  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS  5  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS  6  SEP 11  CA/CAplus enhanced with more pre-1907 records
 NEWS  7  SEP 21  CA/CAplus fields enhanced with simultaneous left and right
                  truncation
 NEWS  8  SEP 25  CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS  9  SEP 25  CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 10  SEP 25  CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 11  SEP 28  CEABA-VTB classification code fields reloaded with new
                  classification scheme
 NEWS 12  OCT 19  LOGOFF HOLD duration extended to 120 minutes
 NEWS 13  OCT 19  E-mail format enhanced
 NEWS 14  OCT 23  Option to turn off MARPAT highlighting enhancements available
 NEWS 15  OCT 23  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
 NEWS 16  OCT 23  The Derwent World Patents Index suite of databases on STN
                  has been enhanced and reloaded
 NEWS 17  OCT 30  CHEMLIST enhanced with new search and display field
 NEWS 18  NOV 03  JAPIO enhanced with IPC 8 features and functionality

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:33:00 ON 06 NOV 2006

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'REGISTRY' ENTERED AT 14:36:04 ON 06 NOV 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 NOV 2006 HIGHEST RN 912451-62-8
DICTIONARY FILE UPDATES: 5 NOV 2006 HIGHEST RN 912451-62-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10507006.str





chain nodes :
9 15 16 17 20 21 22 23 24 25 27 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 11 12 13 14
chain bonds :
1-27 1-28 2-29 2-30 5-31 5-32 6-9 11-20 12-16 13-15 16-17 17-25 20-21 21-22 21-24 22-23

ring bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8 7-11 8-14 11-12 12-13 13-14
exact/norm bonds :
1-2 1-5 1-27 1-28 2-3 2-29 2-30 3-4 3-6 4-5 4-8 5-31 5-32 6-7 6-9
11-20 12-16 13-15 16-17 17-25 20-21 21-22 21-24 22-23
normalized bonds :
7-8 7-11 8-14 11-12 12-13 13-14
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 20:Atom 21:CLASS
22:CLASS 23:Atom 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS
31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:36:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE,

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:36:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       97 TO ITERATE

100.0% PROCESSED       97 ITERATIONS                                12 ANSWERS
SEARCH TIME: 00.00.01

L3           12 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     166.94     167.99

FILE 'CAPLUS' ENTERED AT 14:36:43 ON 06 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Nov 2006  VOL 145 ISS 20
FILE LAST UPDATED: 5 Nov 2006  (20061105/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4            2 L3

=> d ibib abs hitstr tot

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:436085  CAPLUS
DOCUMENT NUMBER:         143:133316
TITLE:                   Hantzsch Synthesis of Pyrazolo[1',2':1,2]pyrazolo[3,4-
                         b]pyridines: Partial Agonists of the Calcitonin
                         Receptor
AUTHOR(S):               Boros, Eric E.; Cowan, David J.; Cox, Richard F.;
                         Mebrahtu, Makda M.; Rabinowitz, Michael H.; Thompson,
                         James B.; Wolfe, Lawrence A., III
CORPORATE SOURCE:        GlaxoSmithKline Research and Development, Research
                         Triangle Park, NC, 27709, USA
SOURCE:                  Journal of Organic Chemistry (2005), 70(13), 5331-5334
```

CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:133316
GI



I

AB Small mol. calcitonin receptor agonists are of potential utility in the treatment and prevention of osteoporosis. 3-Amino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one (I) was a useful intermediate in the synthesis of pyrazolopyridine calcitonin receptor partial agonists II [R = 2-furylmethyl, 3-pyridylmethyl, 3-FC6H4CH2, 1-indanyl; X = O, S, CH:CH; Y = F, CF3]. The corresponding dihydropyridines were conveniently prepared by reaction of I with Knoevenagel adducts of 4-YC6H4CH2CH2COCH2CO2Et (III) or by a three component reaction with I, III, and 4-OCHC6H4CO2H. Oxidation to pyridine and amide formation afforded I.

IT 858671-20-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Hantzsch synthesis of pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridines as partial agonists of the calcitonin receptor)

RN 858671-20-2 CAPLUS

CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-furanyl]-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:737759 CAPLUS
DOCUMENT NUMBER: 139:261291
TITLE: Preparation of condensed heterocyclic compounds such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivatives as calcitonin agonists
INVENTOR(S): Bhandari, Ashok; Boros, Eric Eugene; Cowan, David John; Handlon, Anthony Louis; Hyman, Clifton Earl; Oplinger, Jeffrey Alan; Rabinowitz, Michael Howard; Turnbull, Philip Stewart
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003076440	A1	20030918	WO 2003-US5605		20030224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003213266	A1	20030922	AU 2003-213266		20030224
US 2005107419	A1	20050519	US 2003-507006		20030224
PRIORITY APPLN. INFO.:			US 2002-362011P	P	20020306
			WO 2003-US5605	W	20030224

OTHER SOURCE(S): MARPAT 139:261291
GI



I

AB The title compds. [I; R = each (un)substituted aryl, heteroaryl, alkyl, or cycloalkyl, further wherein said aryl, heteroaryl, alkyl, or cycloalkyl; Z = H, alkyl, halogen, CO2R5, CON(R5)2, CONHN(R5)2, NHCON(R5)2, SO2N(R5)2, CH2NHCOR5, NO2, N(R5)2, NHCOR5, N(R5)SO2N(R5)2, OR5, CH2N(R5)2, CH2CON(R5)2, CH2CO2R5, (un)substituted heteroaryl; R5 = independently H, alkyl, trifluoromethyl, each (un)substituted aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocyclyl, fused cycloalkylaryl, or fused heterocyclylaryl; R1 = H, alkyl, CO2R5, COR5, CON(R5)2, cyano, NO2, N(R5)2, SO2R5, SO2N(R5)2, NHCOR5, NHCON(R5)2; R2 = alkyl, CF3, alkoxy, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyaryl, further wherein said alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be substituted with one or more of halogen, CF3, or alkoxy; or R1 and R2 combine to form a 5- or 6-membered ring, optionally containing one or more heteroatom, optionally containing one or more degrees of unsatn., and optionally substituted one or more times with oxo, hydroxy, halogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, further wherein said alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be substituted with one or more of halogen, CF3, or alkoxy; A = C, N; Y = C, N; X = S, O, N(R5), C(R5)2, SO2; n = 1, 2, 3, or 4], salts, solvates, and pharmaceutically functional derivs. thereof are prepared These compds. are useful in the treatment and prevention of diseases or conditions which are related to irregular calcification or those mediated by calcitonin. They are used in therapies for osteopenia and osteoporosis in men and women; reduction in the risk of fractures, both vertebral and nonvertebral; Paget's disease; bone fracture or deficiency; primary or secondary hyperparathyroidism; periodontal disease or defect; metastatic bone disorder; osteolytic bone disease; post-plastic surgery; post-prosthetic joint surgery; postdental implantation; hypercalcemia; bone pain, general pain, and hyperalgesia; conditions associated with inhibiting gastric secretion; gastrointestinal disorders; osteoarthritis and rheumatoid arthritis; renal osteodystrophy; obesity by induction of satiety; and male infertility. Thus, 4-[3-(Ethoxycarbonyl)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1'2':1,2]pyrazolo[3,4-b]pyridin-4-yl]benzoic acid was condensed with furfurylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and HOBT-H2O in DMF at room temperature for 4 h to give 2-[2-(4-fluorophenyl)ethyl]-4-[4-[[(2-furylmethyl)amino]carbonyl]phenyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylate (II). In an CRE-luciferase reporter assay, II activated the human calcitonin-2 receptor (HCT2R) expressed in CHO-6CRE-luciferase cells with E50 of ≤10 nM.

IT 603998-46-5P 603998-48-7P 603998-49-8P
603998-50-1P 603998-52-3P 603998-54-5P
603998-74-9P 603998-75-0P 603998-76-1P
603998-84-1P 603998-86-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of condensed heterocyclic compds. such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivs. as calcitonin agonists for drugs)

RN 603998-46-5 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[(2,3-dihydro-1H-

inden-1-yl)amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-48-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]-2-furanyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-49-8 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-50-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-thiazolyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-52-3 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-oxazolyl]-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-54-5 CAPLUS
CN Benzamide, 4-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-3-[(trifluoroacetyl)amino]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-[(1R)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-74-9 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-2-(4-methylpentyl)-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-75-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(3,3,3-trifluoropropyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-76-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[(2,4-difluorophenyl)methyl]-4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-84-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-nitrophenyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-86-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(phenylmethyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:33:00 ON 06 NOV 2006)

FILE 'REGISTRY' ENTERED AT 14:36:04 ON 06 NOV 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 12 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:36:43 ON 06 NOV 2006
L4 2 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.14	179.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

STN INTERNATIONAL LOGOFF AT 14:38:00 ON 06 NOV 2006